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Agonistic antibodies specific for members of the tumor necrosis factor receptor protein family hold great
promise for immunotherapy of cancer. In this issue of Cancer Cell, White and colleagues provide evidence
that the human IgG2 subclass may represent a superior backbone for the use of these antibodies in human
therapy.Cytotoxic tumor specific antibodies have
become the standard of care in patients
with malignant lymphoma or breast can-
cer. Furthermore, the CTLA-4-specific
antibody ipilimumab, which depletes
regulatory T cells in the tumor microen-
vironment, has shown great success in
cancer patients with metastatic mela-
noma (Simpson et al., 2013). In this issue
of Cancer Cell, White et al. (2015) inves-
tigate how different human IgG sub-
classes impact the activity of a third class
of antibodies holding great promise for
enhancing anticancer therapies. These
so-called agonistic antibodies target cos-
timulatory molecules such as CD40, a
member of the tumor necrosis factor re-
ceptor (TNFR) protein family, on dendritic
cells to achieve optimal tumor-specific
T cell responses, or members of the death
receptor (DR) family of proteins present
on tumor cells to induce apoptotic tumor
cell death (Moran et al., 2013). Using
these antibodies in combination with
cytotoxic antibodies would allow a dual
attack on tumor cells by a reduction of
tumor mass via the cytotoxic antibody
and an induction of strong antitumor
T cell responses via the immunomodula-
tory antibody. While the activity of cyto-
toxic antibodies is critically dependent
on the interaction with activating Fcg
receptors (FcgR) expressed on innate
immune effector cells, one of the big
surprises in the field of therapeutic anti-
bodies was the discovery that the immu-
nomodulatory activity of agonistic anti-
bodies was also dependent on FcgRs
and, even more unexpected, predomi-
nantly on the inhibitory FcgRIIB (Li and
Ravetch, 2011; White et al., 2011; Wilson10 Cancer Cell 27, January 12, 2015 ª2015 Eet al., 2011; Xu et al., 2003). In light of
the great clinical success of the second
generation cytotoxic antibodies, which
have been engineered for enhanced
binding to activating FcgRs, this finding
provided a roadmap for optimizing the
activity of agonistic antibodies by gener-
ating antibody variants with enhanced
binding to the inhibitory FcgRIIB (Nimmer-
jahn and Ravetch, 2012). Of note, while
binding of the agonistic antibody to
FcgRIIB was critical, this effect did not
require triggering of FcgRIIB-dependent
signaling pathways, suggesting that
FcgRIIB was acting as a passive cross-
linker to achieve optimal induction of
signaling via the target molecule bound
by the agonistic antibody.
A potential issue that may arise in the
clinic is that FcgRIIB may not be ex-
pressed at sufficiently high levels in all
tissues, which may preclude optimal
activity of at least some agonistic anti-
bodies (Li and Ravetch, 2012). Moreover,
an unwanted high level of crosslinking
may result in severe side effects, such
as an uncontrolled release of proinflam-
matory cytokines, which, according to
recent data may at least in part explain
the severe side effects in a clinical trial
with a superagonistic CD28-specific anti-
body (Bartholomaeus et al., 2014). Of
note, recent studies emphasize that
even human IgG subclasses, such as
IgG4, widely considered to have no sig-
nificant binding to FcgRs can indeed
interact with these receptors if the amount
of antibodies bound to their target is high
enough (Lux et al., 2013).
White et al. (2015) now present an
elegant solution to this problem by inves-lsevier Inc.tigating the impact of different human
IgG backbones on agonistic antibody
activity, demonstrating that select human
IgG subclasses can trigger an agonistic
activity autonomously without the need
for higher-order crossliniking via FcgRs.
These studies also emphasize the differ-
ences between the mouse and human
antibody and the FcgR system. Whereas
select IgG subclasses in mice, such as
IgG1, show a strong binding to the inhi-
bitory FcgRIIB, human IgG subclasses
have a much lower affinity for their human
counterpart (Figure 1). Indeed, agonistic
antibodies with a human IgG1 backbone
had to be engineered for enhanced bind-
ing to FcgRIIB to become therapeutically
active in human FcgRIIB-transgenic
mice (Li and Ravetch, 2012).
White et al. (2015) now provide con-
vincing evidence that the human IgG2
backbone may represent a natural solu-
tion to this problem. By generating human
IgG subclass switch variants specific for
CD40, CD28, or 4-1BB (CD137), they
show that the IgG2 subclass is superior
to other IgG subclasses for induction of
B cell proliferation, dendritic cell activa-
tion, and induction of tumor-specific cyto-
toxic T cell responses. This activity was
FcgR independent in vivo, because these
agonistic antibodies were fully active as
F(ab)2 fragments or in mice lacking the
inhibitory FcgRIIB. In a series of elegant
experiments White et al. (2015) show
that especially the hinge and CH1 do-
mains of human IgG2, which are charac-
terized by a set of distinct disulfide bonds,
are critical for this effect. Thus, grafting
the human IgG2 hinge and CH1-domains
on an IgG1-backbone was sufficient to
Figure 1. Pathways Responsible for the Activity of Mouse and Human Agonistic Antibody
Activity In Vivo
In mice, IgG1 antibodies have sufficiently high activity to mediate agonistic effects via binding to the
inhibitory FcgRIIB. In humans, the IgG2 subclass has an intrinsic capacity to trigger agonistic antibody-
dependent effects and does not require higher order crosslinking. See text for further details.
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Previewstransfer the agonistic activity to another
antibody subclass. Going into more
detail, they show that a specific subfrac-
tion of human IgG2, the so-called h2B
isoform which is characterized by a
more rigid structure compared to its h2A
counterpart, is the major isoform respon-sible for this FcgR independent activity.
This is of major importance, because the
presence of the h2A isoform was not
only inactive but was also able to block
the agonistic activity of the h2B isoform.
Taking these issues into account, White
et al. (2015) show that protein engineeringCancer Cell 2of the IgG2 backbone allows locking of
the antibody in the h2B isoform, thereby
obtaining optimal activity in vivo. Taken
together, this study provides a clear-cut
therapeutic avenue of how agonistic anti-
bodies can be engineered with respect
to safety and enhanced activity to treat
human cancer.REFERENCES
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